SCHEMBL7084839

SCHEMBL7084839

NS(=O)(=O)c1ccc(-c2nc(C(F)(F)F)[nH]c2-c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.59
ALOX5 P09917 1/20 0.53
ESR1 P03372 1/20 0.51
ESR2 Q92731 1/20 0.51
PTGS2 P35354 10/20 0.50
PTGS1 P23219 6/20 0.50
CYP2C9 P11712 1/20 0.45
MAPK13 O15264 1/20 0.45
RAF1 P04049 1/20 0.45
MAPK12 P53778 1/20 0.45
MAPK11 Q15759 1/20 0.45
MAPK14 Q16539 1/20 0.45
PDPK1 O15530 1/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
MAPT P10636 1/20 0.44
BRAF P15056 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7090916 0.90 ESR1 (0.65) ALOX5ESR1ESR2PTGS2PTGS1
SCHEMBL7085186 0.90 ALOX5 (0.62) ALOX5ESR1ESR2PTGS2PTGS1
SCHEMBL7089340 0.88 CA2 (0.50) KIF11ALOX5ESR1ESR2PTGS2
SCHEMBL7088536 0.88 PTGS2 (0.51) ALOX5ESR1ESR2PTGS2PTGS1
SCHEMBL7087388 0.88 PTGS2 (0.50) KIF11ALOX5ESR1ESR2PTGS2
SCHEMBL7084237 0.87 PTGS2 (0.55) ALOX5ESR1ESR2PTGS2PTGS1
SCHEMBL7089441 0.85 PTGS1 (0.50) ALOX5ESR1ESR2PTGS2PTGS1
SCHEMBL7090091 0.85 CA2 (0.50) KIF11ALOX5ESR1ESR2PTGS2
SCHEMBL7085177 0.85 PTGS2 (0.52) KIF11ALOX5ESR1ESR2PTGS2
SCHEMBL7089177 0.85 PTGS2 (0.49) KIF11ALOX5ESR1ESR2PTGS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5620999-A ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT G.D. SEARLE & CO. 1997-04-15 US claimed
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
EP-1211244-A2 4,5-substitued imidazolyl compounds for the treatment of inflammation G.D. Searle & Co. (US) 2002-06-05 EP disclosed
EP-0772601-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-05-14 EP disclosed
US-5620999-A ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT G.D. SEARLE & CO. 1997-04-15 US disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 KIF11 4847/4885ALOX5 74/4885ESR1 3743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.